Stryker Corporation $SYK Shares Sold by Westpac Banking Corp

Westpac Banking Corp trimmed its holdings in shares of Stryker Corporation (NYSE:SYK) by 1.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,394 shares of the medical technology company’s stock after selling 237 shares during the period. Westpac Banking Corp’s holdings in Stryker were worth $7,277,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SYK. Consolidated Portfolio Review Corp raised its stake in shares of Stryker by 4.2% in the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after acquiring an additional 26 shares during the period. Princeton Global Asset Management LLC increased its holdings in Stryker by 16.9% in the 2nd quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock valued at $71,000 after purchasing an additional 26 shares in the last quarter. Sunflower Bank N.A. raised its position in Stryker by 4.0% in the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after purchasing an additional 27 shares during the period. Pitti Group Wealth Management LLC lifted its stake in shares of Stryker by 3.2% during the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock worth $341,000 after purchasing an additional 27 shares in the last quarter. Finally, Sachetta LLC boosted its position in shares of Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after buying an additional 27 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Price Performance

SYK opened at $362.39 on Friday. The company has a market capitalization of $138.59 billion, a P/E ratio of 48.00, a PEG ratio of 2.66 and a beta of 0.94. The company has a 50-day moving average of $371.96 and a 200-day moving average of $381.22. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same period last year, the firm earned $2.87 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 520,500 shares of company stock valued at $184,803,065 over the last quarter. Company insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on SYK. Needham & Company LLC reiterated a “buy” rating and set a $448.00 target price on shares of Stryker in a report on Friday. Rothschild Redb raised shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Redburn Partners set a $420.00 target price on shares of Stryker in a research report on Thursday, September 18th. Royal Bank Of Canada restated an “outperform” rating and issued a $435.00 target price on shares of Stryker in a research note on Friday. Finally, Rothschild & Co Redburn started coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target for the company. Thirteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $434.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.